Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Inv. presentation
ARS Pharmaceuticals, Inc. (SBTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates ARS continues engagement with U.S. FDA on final labeling and post-marketing commitments for the neffy® new drug application; PDUFA target action date set for September 19, 2023 Ended second quarter with $252.2 million in cash, cash equivalents and short-term investments; well-capitalized to support anticipated launch of neffy in the U.S. and an expected operating runway of at least three years SAN DIEGO – August 10, 2023 -ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the second quarter of 2023. &#x2..."
06/28/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/16/2023 8-K Investor presentation
Docs: "Corporate Presentation"
05/15/2023 8-K Quarterly results
Docs: "ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment of Allergic Reactions , Including Anaphylaxis New Drug and Marketing Authorization Applications for neffy Under Review with FDA and EMA, Respectively; FDA PDUFA Target Action Date Anticipated mid-2023 $264.5 Million in Cash, Cash Equivalents and Short-term Investments to Support Operating Runway for the Next Three Years, Including the Planned Commercialization of neffy in the United States SAN DIEGO – May 15, 2023 -ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead t..."
05/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Company comments to FDA Briefing Document",
"Company comments to FDA Briefing Document"
03/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA and EMA; FDA PDUFA Target Action Date Anticipated in Mid-2023 Strong Financial Position with $274.4 Million in Cash, Cash Equivalents and Short-term Investments to Support Operating Runway for the Next Three Years SAN DIEGO – March 23, 2023 - ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today highlighted recent progress and reported fourth quarter and full year 2022 financial results. “This is an incredibly exciting ti..."
03/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Company Presentation",
"Company Presentation"
02/22/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement  Interactive Data
02/14/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Company Presentation",
"Company Presentation"
01/17/2023 8-K/A Quarterly results
12/09/2022 8-K Quarterly results
12/06/2022 8-K Quarterly results
11/08/2022 8-K Entered into consulting agreement
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC.,",
"Certificate of Amendment to Amended and Restated Certificate of Incorporation of Silverback Therapeutics, Inc",
"Certificate of Merger",
"Warrant to purchase stock issued to Silicon Valley Bank, as amended on December 7, 2020",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. Confidential LICENSE AGREEMENT between ARS PHARMACEUTICALS, INC. and AEGIS THERAPEUTICS, LLC",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. Confidential COLLABORATION AND DISTRIBUTION AGREEMENT",
"Cover Page Interactive Data File (embedded within the Inline XBRL document",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL.",
"9. Section 409A. It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1, 1.409A-1 and 1.409A-1, and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement will be construed in a manner that complies with Section 409A. For purposes of Code Section 409A ), Executive's right to receive any installment payments under this Agreement shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. ..."
11/02/2022 8-K Other Events  Interactive Data
10/27/2022 8-K Quarterly results
10/21/2022 8-K Quarterly results
09/30/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "Second Amendment to Lease, by and between the Company and BMR-500 Fairview Avenue LLC",
"Second Amendment to Lease, by and between the Company and BMR-500 Fairview Avenue LLC"
09/02/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Letter Agreement, by and between Silverback and Russ Hawkinson"
07/21/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
03/17/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/10/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update"
09/16/2021 8-K Quarterly results
09/13/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
07/02/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
06/09/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
12/08/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 8, 2020 Silverback Therapeutics, Inc. Delaware 001-39756 81-1489190 500 Fairview Ave N, Suite 600 Seattle, Washington 98109 Registrant's telephone number, including area code: 456-2900 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐...",
"Amended and Restated Certificate of Incorporation of the Registrant",
"Amended and Restated Bylaws of the Registrant",
"Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares Seattle, WA, December 8, 2020 - Silverback Therapeutics, Inc. , a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the closing of its previously announced initial public offering of 13,225,000 shares of its common stock, which includes 1,725,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $21.00 per share. Including the option exercise, the aggregat..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy